Zhiyong Yang

Zhiyong Yang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Frontiers in Surgery
Verified
Journal Article
Open access
JXJudi Xu
Judi Xu
HLHedai Liu
Hedai Liu
GNGuoying Ni
Guoying Ni
YHYan Huang
Yan Huang
YHYing Huang
Ying Huang
ZYZhiyong Yang
Zhiyong Yang
A 54-year-old male was diagnosed with extensive liver metastasis and small nodule metastasis in the lungs from gastric adenocarcinoma [Her-2 (−)]. The patient achieved significant partial response (PR) after chemotherapy combined with anti-angiogenesis therapy but developed progressive disease (PD) after 5 months. Then, the chemotherapeutic and anti-angiogenic drugs were replaced. Meanwhile, the delivery route of some chemotherapeutic drugs was changed, and some chemotherapeutic drugs were given via transcatheter arterial chemoembolization (TACE) to achieve PR, and PD developed after 3 months of remission maintenance. During chemotherapy combined with anti-angiogenesis, the application of programmed cell death-1 (PD-1) inhibitor achieved PR again and maintained for 5 months before disease progression. The progression of the lesions in the left lobe of the liver and the hepatic hilar lymph nodes was significant. Hence, chemotherapy was terminated and gamma stereotactic body radiation therapy (SBRT) was performed on left lobe lesions and hilar lymph nodes. The lesions both inside and outside the radiation field regressed significantly, reaching PR and abscopal effects. The immune-related adverse events (irAEs) occurred, including erythema and black and luster hair. The abscopal effects of lesion reduction in the radiation field and the enhancement of the immune function stimulated by radiation are a highlight of the combination of radiation and immunotherapy. In the end, the patient died of gastrointestinal failure, with overall survival of 18 months.


25 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JXJudi Xu
Judi Xu
YHYing Huang
Ying Huang
YNYufeng Ni
Yufeng Ni
YHYan Huang
Yan Huang
QHQian Huang
Qian Huang
HLHedai Liu
Hedai Liu
With the intensification of population aging, the number of elderly cancer patients has increased dramatically in recent years. However, the treatment of aged cancer patients, particularly those who are not eligible for surgery, is still a challenge. Thus, in this study, we retrospectively summarized and analyzed the clinical effects of radiotherapy in 43 late-line patients with advanced bladder cancer, with an average age of 77.3 ± 5.1 years. All patients were pathologically diagnosed with transitional epithelial carcinoma of the bladder, persistent bleeding, no condition for surgery, and were not suitable for chemotherapy. After thorough communication, all patients were treated with radiotherapy. As a result, the degree of bleeding gradually decreased after 5 rounds of 10Gy radiotherapy. After 15 rounds of 30Gy radiotherapy, the gross hematuria disappeared, and the success rate of radiotherapy in preventing bleeding reached 100%. At the end of follow-up, 24 patients passed away, and 19 patients were alive. The median survival time (OS) was 14 months. Statistical analysis revealed that the survival time of patients significantly differed between radical and palliative radiotherapy. The survival time of patients with advanced cancer is usually less than 3 months in the clinic, whereas the OS of patients (14 months) in this study far exceeded that reported previously. Therefore, radiotherapy can not only stop bleeding and relieve symptoms but also prolong patient survival time, offering an option for elderly patients with advanced bladder cancer to control tumor progression and improve quality of life.